1 |
Horta-baas G. Patient-Reported Outcomes in Rheumatoid Arthritis: A Key Consideration for Evaluating Biosimilar Uptake? PROM 2022;Volume 13:79-95. [DOI: 10.2147/prom.s256715] [Reference Citation Analysis]
|
2 |
Lin I, Melsheimer R, Bhak RH, Lefebvre P, DerSarkissian M, Emond B, Lax A, Nguyen C, Wu M, Young-Xu Y. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin 2022;:1-33. [PMID: 35125053 DOI: 10.1080/03007995.2022.2037846] [Reference Citation Analysis]
|
3 |
Hariprasad SM, Gale RP, Weng CY, Ebbers HC, Rezk MF, Tadayoni R. An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review. Ophthalmol Ther 2022. [PMID: 35278204 DOI: 10.1007/s40123-022-00488-w] [Reference Citation Analysis]
|
4 |
Tolonen HM, Falck J, Kurki P, Ruokoniemi P, Hämeen-Anttila K, Shermock KM, Airaksinen M. Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic Review. BioDrugs 2021. [PMID: 34398421 DOI: 10.1007/s40259-021-00493-8] [Reference Citation Analysis]
|